Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.

Oliva P, Decio A, Castiglioni V, Bassi A, Pesenti E, Cesca M, Scanziani E, Belotti D, Giavazzi R.

Br J Cancer. 2012 Jul 10;107(2):360-9. doi: 10.1038/bjc.2012.261. Epub 2012 Jun 19.

2.

Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.

Decio A, Cesca M, Bizzaro F, Porcu L, Bettolini R, Ubezio P, Taraboletti G, Belotti D, Giavazzi R.

Clin Exp Metastasis. 2015 Oct;32(7):647-58. doi: 10.1007/s10585-015-9734-1. Epub 2015 Jul 17.

PMID:
26185056
3.

The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.

Garofalo A, Naumova E, Manenti L, Ghilardi C, Ghisleni G, Caniatti M, Colombo T, Cherrington JM, Scanziani E, Nicoletti MI, Giavazzi R.

Clin Cancer Res. 2003 Aug 15;9(9):3476-85.

4.

Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.

Konner JA, Grabon DM, Gerst SR, Iasonos A, Thaler H, Pezzulli SD, Sabbatini PJ, Bell-McGuinn KM, Tew WP, Hensley ML, Spriggs DR, Aghajanian CA.

J Clin Oncol. 2011 Dec 10;29(35):4662-8. doi: 10.1200/JCO.2011.36.1352. Epub 2011 Nov 7.

5.
6.
7.

Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.

Mabuchi S, Terai Y, Morishige K, Tanabe-Kimura A, Sasaki H, Kanemura M, Tsunetoh S, Tanaka Y, Sakata M, Burger RA, Kimura T, Ohmichi M.

Clin Cancer Res. 2008 Dec 1;14(23):7781-9. doi: 10.1158/1078-0432.CCR-08-0243.

8.

Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.

Gaikwad SM, Thakur B, Sakpal A, Singh RK, Ray P.

Int J Biochem Cell Biol. 2015 Apr;61:90-102. doi: 10.1016/j.biocel.2015.02.001. Epub 2015 Feb 11.

PMID:
25681684
9.

Medical therapy of advanced malignant epithelial tumours of the ovary.

Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.

Forum (Genova). 2000 Oct-Dec;10(4):323-32. Review.

PMID:
11535983
10.

The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.

Cesca M, Frapolli R, Berndt A, Scarlato V, Richter P, Kosmehl H, D'Incalci M, Ryan AJ, Giavazzi R.

Neoplasia. 2009 Nov;11(11):1155-64.

11.

Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.

O'Malley DM, Richardson DL, Rheaume PS, Salani R, Eisenhauer EL, McCann GA, Fowler JM, Copeland LJ, Cohn DE, Backes FJ.

Gynecol Oncol. 2011 May 1;121(2):269-72. doi: 10.1016/j.ygyno.2011.01.009. Epub 2011 Feb 18.

PMID:
21315428
12.

Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer.

Shah DK, Veith J, Bernacki RJ, Balthasar JP.

Cancer Chemother Pharmacol. 2011 Oct;68(4):951-8. doi: 10.1007/s00280-011-1566-3. Epub 2011 Feb 9.

PMID:
21305289
13.

Overexpression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and Its inhibition potentiates cisplatin-induced apoptosis.

Uddin S, Jehan Z, Ahmed M, Alyan A, Al-Dayel F, Hussain A, Bavi P, Al-Kuraya KS.

Mol Med. 2011;17(7-8):635-45. doi: 10.2119/molmed.2011.00046. Epub 2011 Mar 21.

14.

Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial.

Zhao H, Li X, Chen D, Cai J, Fu Y, Kang H, Gao J, Gao K, Du N.

Med Oncol. 2015 Feb;32(2):292. doi: 10.1007/s12032-014-0292-1. Epub 2015 Jan 22.

PMID:
25609006
15.

High efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors.

Sommariva M, de Cesare M, Meini A, Cataldo A, Zaffaroni N, Tagliabue E, Balsari A.

J Transl Med. 2013 Jan 29;11:25. doi: 10.1186/1479-5876-11-25.

16.

Bevacizumab and ovarian cancer.

Sato S, Itamochi H.

Curr Opin Obstet Gynecol. 2012 Feb;24(1):8-13. doi: 10.1097/GCO.0b013e32834daeed. Review.

PMID:
22123222
17.

Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.

Thaker PH, Yazici S, Nilsson MB, Yokoi K, Tsan RZ, He J, Kim SJ, Fidler IJ, Sood AK.

Clin Cancer Res. 2005 Jul 1;11(13):4923-33.

18.

Bevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.

Dhillon S.

Drugs. 2012 May 7;72(7):917-30. doi: 10.2165/11208940-000000000-00000. Review.

PMID:
22515620
19.

Picropodophyllin inhibits epithelial ovarian cancer cells in vitro and in vivo.

Lu X, Wang L, Mei J, Wang X, Zhu X, Zhang Q, Lv J.

Biochem Biophys Res Commun. 2013 Jun 7;435(3):385-90. doi: 10.1016/j.bbrc.2013.04.097. Epub 2013 May 9.

PMID:
23665331
20.

HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma.

Bu R, Uddin S, Bavi P, Hussain AR, Al-Dayel F, Ghourab S, Ahmed M, Al-Kuraya KS.

Lab Invest. 2011 Jan;91(1):124-37. doi: 10.1038/labinvest.2010.136. Epub 2010 Jul 26.

Items per page

Supplemental Content

Write to the Help Desk